COLOMBO NICOLETTA
Pubblicazioni
Vergote, I., Copeland, L., Van Gorp, T., Laenen, A., Scambia, G., Thaker, P., et al. (2025). Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. EUROPEAN JOURNAL OF CANCER, 219(26 March 2025) [10.1016/j.ejca.2025.115306]. Dettaglio
Scambia, G., Villalobos Valencia, R., Colombo, N., Cibula, D., Leath, C., Bidzinski, M., et al. (2025). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. JOURNAL OF CLINICAL ONCOLOGY, 43(12), 1408-1416 [10.1200/JCO.24.00933]. Dettaglio
Fumagalli, D., Jayraj, A., Olearo, E., Capasso, I., Hsu, H., Tzur, Y., et al. (2025). Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35(3) [10.1016/j.ijgc.2025.101664]. Dettaglio
De Vitis, L., Schivardi, G., Gaeta, A., Caruso, G., Rosanu, M., Ribero, L., et al. (2025). External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35(6 (June 2025)) [10.1016/j.ijgc.2025.101756]. Dettaglio
Poveda, A., Lheureux, S., Colombo, N., Cibula, D., Elstrand, M., Weberpals, J., et al. (2025). Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial. GYNECOLOGIC ONCOLOGY, 197(June 2025), 74-82 [10.1016/j.ygyno.2025.04.580]. Dettaglio